Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP 87 EV-to-Revenue is 1.90 as of Sep. 10, 2026, which is 40% below its 10-year median of 3.15. GuruFocus rates ASX:AFP with a GF Score™ of 87/100 and a GF Value™ of A$3.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 963 Drug Manufacturers companies, AFT Pharmaceuticals ranks better than 59.29% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AFT Pharmaceuticals's enterprise value is A$410.6 Mil.
AFT Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was A$216.0 Mil. Therefore, AFT Pharmaceuticals's EV-to-Revenue for today is 1.90.
The historical rank and industry rank for AFT Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
ASX:AFP'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.05 Med: 3.15 Max: 5.47
Current: 2
During the past 11 years, the highest EV-to-Revenue of AFT Pharmaceuticals was 5.47. The lowest was 1.05. And the median was 3.15.
ASX:AFP's EV-to-Revenue is ranked better than 59.29% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.49
vs ASX:AFP: 2.00
AFT Pharmaceuticals's share price for today is A$3.49.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Mar. 2026 was A$2.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals EV-to-Revenue Related Terms
AFT Pharmaceuticals EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AFP vs ZTS, UTHR, VTRS: EV-to-Revenue Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals EV-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's EV-to-Revenue falls into.
AFT Pharmaceuticals's current Enterprise Value is A$410.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was A$216.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (ASX:AFP) has a EV-to-Revenue of 1.90 as of Sep. 10, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on AFT Pharmaceuticals and its competitors. This is 40% below median its historical median of 3.15. Over the past decade, AFT Pharmaceuticals' EV-to-Revenue has ranged from 1.05 to 5.47. According to the industry distribution chart, AFT Pharmaceuticals ranks #392 out of 963 companies in the Drug Manufacturers industry, placing it in the top 40.7%.
Is AFT Pharmaceuticals' EV-to-Revenue too high?
AFT Pharmaceuticals' current EV-to-Revenue of 1.90 is 40% below median its 10-year median of 3.15. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 5.47. The Drug Manufacturers industry median EV-to-Revenue is 2.49. AFT Pharmaceuticals' value of 1.90 is 23.7% below this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #392 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' EV-to-Revenue compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #392 out of 963 companies for EV-to-Revenue. This puts AFT Pharmaceuticals in the upper half of its industry. The industry median EV-to-Revenue is 2.49. AFT Pharmaceuticals' value of 1.90 is 23.7% below this benchmark. Historically, AFT Pharmaceuticals' own EV-to-Revenue has ranged from 1.05 to 5.47 over the past decade. While the company's 10-year median is 3.15 vs. the industry median of 2.49, AFT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Drug Manufacturers company?
The median EV-to-Revenue among Drug Manufacturers companies is 2.49, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current EV-to-Revenue of 1.90 is 23.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-Revenue is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current EV-to-Revenue is 1.90, which is 40% below median its own 10-year median of 3.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.50, compared to a current price of A$3.49 — trading 0.3% below its estimated fair value. The current EV-to-Revenue is 1.90, which is 40% below median its 10-year median of 3.15 and 23.7% below the Drug Manufacturers industry median of 2.49. AFT Pharmaceuticals' overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current EV-to-Revenue is 1.90 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of A$3.49 is trading 0.3% below its estimated GF Value™ of A$3.50.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
EV-to-Revenue: 1.90 (40% below median its 10-year median of 3.15)
GF Value™: A$3.50 vs. price of A$3.49 (0.3% below fair value)
Industry Position: 23.7% below the Drug Manufacturers median (#392 of 963)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
87GF Score
Get the complete analysis for ASX:AFP
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
